Literature DB >> 12869647

Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus.

Delphine Skrzydelski1, Anne-Marie Lhiaubet, Antony Lebeau, Patricia Forgez, Misa Yamada, Emmanuel Hermans, William Rostene, Didier Pelaprat.   

Abstract

In this work, we evidenced characteristic features of agonist-induced trafficking of receptor stimulus for the rat neurotensin receptor 1 (NTS1). Thus, reverse potency orders between two agonists, EISAI-1 and neuromedin N, were observed in inositol 1,4,5-trisphosphate and cAMP assays in Chinese hamster ovary cells transfected with this receptor. Indeed, compared with other agonists, EISAI-1 presented lower relative potency toward inositol 1,4,5-trisphosphate production than toward cAMP accumulation, guanosine 5'-O -(3-[35 S]thio)triphosphate binding, and [3H]arachidonic acid production. These results indicated pathway-dependent differences in EISAI-1 intrinsic efficacies, favoring activations of Gs- and Gi/o-related pathways over the Gq/11-related pathway. Moreover, although coupling to Gq/11 and Gi/o involved the third intracellular loop and the C-terminal domain of the NTS1 receptor, respectively, we demonstrated that deletion of the latter domain suppressed agonist-induced cAMP accumulation, suggesting that this domain also mediated coupling to Gs. Together, these results indicated that, unlike other agonists, EISAI-1 discriminated between the pathways involving the receptor C-terminal domain and that involving the third intracellular loop. These properties of EISAI-1 were also observed in cortical neurons endogenously expressing the NTS1 receptor. They were further attributed to the functionalization of its COOH end by an ethyl group, because the unesterified analog EISAI-2 presented normal behavior on inositol 1,4,5-trisphosphate production. These findings support the hypothesis of agonist-selective receptor states with distinct conformations or accessibilities of intracellular domains. They also suggest that the differential involvement of these domains in coupling to G proteins might represent a molecular basis for agonist-selective responses through G protein-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869647     DOI: 10.1124/mol.64.2.421

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli.

Authors:  Pascal Egloff; Matthias Hillenbrand; Christoph Klenk; Alexander Batyuk; Philipp Heine; Stefanie Balada; Karola M Schlinkmann; Daniel J Scott; Marco Schütz; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-22       Impact factor: 11.205

2.  Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.

Authors:  Alison C MacKinnon; Uzma Tufail-Hanif; Mark Wheatley; Adriano G Rossi; Christopher Haslett; Michael Seckl; Tariq Sethi
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

3.  Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.

Authors:  Yolande Cordeaux; Adriaan P Ijzerman; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

Review 4.  On the analysis of ligand-directed signaling at G protein-coupled receptors.

Authors:  Frederick J Ehlert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-06       Impact factor: 3.000

Review 5.  The Role of Central Neurotensin in Regulating Feeding and Body Weight.

Authors:  Jariel Ramirez-Virella; Gina M Leinninger
Journal:  Endocrinology       Date:  2021-05-01       Impact factor: 4.736

6.  Suppression of Gq Function Using Intra-Pipette Delivery of shRNA during Extracellular Recording in the Ventral Tegmental Area.

Authors:  Sudarat Nimitvilai; Devinder S Arora; Maureen A McElvain; Mark S Brodie
Journal:  Front Cell Neurosci       Date:  2013-02-12       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.